AlphaStocks
3.8
Weak

NEUROCRINE BIOSCIENCES INC (NBIX)

Health Care / Biotechnology

S&P MidCap 400

$132.63

Scores poorly across most models. Proceed with caution.

Weak

Score based on 4 of 5 models — moderate confidence

#877out of 1127 in Health Care

Is NEUROCRINE BIOSCIENCES INC a Good Investment in 2026?

NEUROCRINE BIOSCIENCES INC (NBIX) scores 3.8 out of 10 on AlphaStocks' composite model, earning a Weak rating. The Piotroski model rates NEUROCRINE BIOSCIENCES INC as Attractive (5/9). However, the Graham model rates it Caution — Significantly above fair value. NEUROCRINE BIOSCIENCES INC currently trades below its estimated fair value of $136, suggesting potential upside. NEUROCRINE BIOSCIENCES INC ranks #877 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

P/E28.4ROE15.3Market Cap14B

Estimated Fair Value

$136.303% below

Trading near estimated fair value.

Model-based estimate, not a price target.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Neutral

Business quality & competitive moat

Graham

Caution

Significantly above fair value

Lynch

Neutral

PEG 2.1 · Fast Grower

Greenblatt

Limited Data

Earnings yield + return on capital

Frequently Asked Questions

Is NEUROCRINE BIOSCIENCES INC (NBIX) a good investment?
Based on AlphaStocks' composite analysis, NEUROCRINE BIOSCIENCES INC (NBIX) scores 3.8 out of 10, earning a Weak rating. This score is below average, suggesting caution. Trading near estimated fair value.
What is NEUROCRINE BIOSCIENCES INC's Piotroski F-Score?
NEUROCRINE BIOSCIENCES INC's Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is NBIX overvalued or undervalued?
Based on AlphaStocks' model-based fair value estimate of $136, NBIX appears undervalued. The stock currently trades 3% below its estimated fair value. Trading near estimated fair value.
How does NBIX compare to other Health Care stocks?
NEUROCRINE BIOSCIENCES INC ranks #877 out of 1127 stocks in the Health Care sector, placing it in the top 78% of its sector by composite score. There are higher-ranked alternatives in this sector worth exploring.
What do investment models say about NBIX?
AlphaStocks evaluates NBIX using five proven investment models. Piotroski: Attractive; Buffett: Neutral; Graham: Caution; Lynch: Neutral. These models are combined into a single composite score of 3.8/10.

Similar Stocks

PARRFTIAZN

Compare NBIX with

NBIX vs PARRNBIX vs FTINBIX vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer